恒指受制10天线倒跌179点 汇控曾低见29.6元 药明生物及碧桂园逆市升
港股连吐三周後,恒指承上周五反覆回升逾百点,今早高开28点,进一步挑战10天线(24,510),最高见24,542无以为继,掉头跌194点,低见24,260,现造24,376,倒跌179点或0.7%,成交额437亿元。
蓝筹股普遍受压,中国商务部实施《不可靠实体清单规定》,据报汇控(00005.HK)等企业或被列入首批清单,以回应美国打压中国企业行为。汇控股价今早曾挫4.4%低见29.6元,再创金融海啸以来新低,现造29.95元,挫3.2%,成交增至5,555万股,涉资16.88亿元。旗下恒生(00011.HK)曾低见116.7元,现跌1.6%。不过,上周五升市火车头内银普遍靠稳,其中建行(00939.HK)续升0.4%报5.34元。此外,内房以碧桂园(02007.HK)表现最好,报9.6元,升2.1%。
美国加利福尼亚州一名法官拒绝就美国商务部有关腾讯(00700.HK)WeChat的禁令发布初步禁令。腾讯高低见527.5元/518元,现造521.5元,反覆续跌近0.7%。小米-W(01810.HK)高开见22.3元,受制10天线(22.4元),掉头低见21.1元,现造21.45元,回落2.7%。阿里巴巴-SW(09988.HK)低见265.4元,现造267元,跌1%,考验10天线(267.4元)支持。苹果上周五挫逾3%,瑞声(02018.HK)现造44.3元,反覆续跌1.9%;但舜宇(02382.HK)高见125.6元,现造124.6元,回升1.4%。
药明生物(02269.HK)建议股份1拆3,该股今早高见197.9元,现造195.2元,续升2.1%。此外,银娱(00027.HK)遭瑞信降级至「中性」及降价至57.4元,该股现造56.15元,反覆续跌2.8%,同业金沙(01928.HK)报32.4元,续跌2.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.